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“Actually, It Is More of
a Guideline Than a Rule”*
Roger S. Blumenthal, MD, Rani K. Hasan, MD
Baltimore, Maryland
In a classic scene from the iconic movie Ghostbusters (1984,
irected by Ivan Reitman), Dr. Peter Venkman (played by
ill Murray) confesses to Dana Barrett (played by Sigourney
eaver), “I make it a rule never to get involved with
ossessed people.” However, after Dana starts to seduce
im, Dr. Venkman replies, “Actually, it is more of a
uideline than a rule!”
See page 1591
Although 90% to 95% of the global population-
attributable risk for myocardial infarction has been ascribed
to 9 modifiable risk factors (1), clinical risk prediction
models for hard events (myocardial infarction, cardiac
death) remain suboptimal. In the United States, 40% to
60% of myocardial infarctions and sudden death occur as
unheralded first manifestations of atherosclerotic cardiovas-
cular disease (ASCVD) (2).
Current U.S. guidelines for identifying and treating
people at increased risk for ASCVD events with proven
therapies, such as aggressive lipid lowering and aspirin, are
based on the Framingham Risk Score (FRS), which is
derived from several generations of long-suffering Cauca-
sian Red Sox fans in Massachusetts—clearly, a unique
group. While useful and widely accepted as an office-based
risk assessment tool, the Adult Treatment Panel (ATP) III
version of the FRS has demonstrated limitations in
predicting the risk of a major atherosclerotic disease
event, particularly among patients with a family history of
premature ASCVD and metabolic syndrome phenotype.
Misclassification of risk results in both under- and over-
treatment of many persons on the basis of the current
ATP III guidelines (3–5).
A number of noninvasive imaging modalities for assess-
ing the degree of subclinical atherosclerosis have been
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disclose.proposed to improve cardiac risk prediction. Professional
organizations have sought to evaluate the literature and
distill the available data into a summary form that is succinct
and conveniently accessible to the busy clinician: hence, the
guideline.
In this issue of the Journal, Ferket et al. (6) present a
systematic review of the guidelines on imaging of asymp-
tomatic coronary artery disease (CAD) published by major
professional organizations between 2003 and early 2010.
The authors based their search on the Institute of Medicine
definition for clinical practice guidelines, and they limited
their selections to guidelines that included recommenda-
tions for imaging for primary prevention of CAD in
presumably healthy nondiabetic populations. They also
performed an assessment of the guideline generation process
for each of the included guidelines using the 7-item Rigor of
Development domain of the Appraisal of Guidelines Re-
search and Evaluation (AGREE) instrument.
Fourteen guidelines published by the U.S. Preventive
Services Task Force (USPSTF), the New Zealand Guide-
lines Group (NZGG), the American Heart Association
(AHA), the American College of Cardiology Foundation
(ACCF), the National Cholesterol Education Program
(NCEP), the Canadian Cardiovascular Society (CCS), and
the Canadian Society of Radiologists (CSR) were included
in the review, with AGREE rigor scores ranging from 93%
(most rigorous) to 21% (least rigorous). Imaging modalities
considered among these guidelines included resting and
exercise electrocardiography, stress echocardiography, myo-
cardial perfusion imaging (single-positron emission com-
puted tomography and positron emission tomography),
computed tomography (CT) and magnetic resonance an-
giography, and CT coronary artery calcium scoring (CAC).
The authors found wide variability with regard to con-
sideration of these testing modalities, with most guidelines
recommending against or noting insufficient evidence for
the majority of noninvasive imaging modalities, with the
only positive recommendations made in reference to
intermediate-risk or selected higher-risk populations. Lo-
gistic regression analysis suggested no relationships between
the likelihood of a guideline recommending for or against
testing and the AGREE rigor score or the proportion of
guideline panelists with reported industry relationships.
Hence, industry relationships did not appear to have any
bearing on the directionality of guideline content in this
exploratory analysis.
The only imaging modality that was addressed by a
majority of the included guidelines was CAC, with 10 of the
14 guidelines making specific recommendations about this
modality as an adjunct to current risk prediction. Among
the intermediate-risk population, 1 guideline (CSR) made a
favorable recommendation for use of CAC, 4 guidelines
(ACCF, AHA, NCEP, CCS) recommended consideration
of CAC, and 3 guidelines (USPSTF, NZGG, ACCF)
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CAC among very low- and high-risk subjects.
The authors note that while there were widespread
inconsistencies and several low AGREE rigor scores among
the included guidelines, there was general support for
consideration of CAC among intermediate-risk subjects.
After a cogent discussion of the limitations of the present
review, Ferket et al. (6) explore the paucity of randomized
controlled trial (RCT) data for early detection of CAD, and
touch on the challenges in generating such data.
While we agree with the authors that RCT data on this
topic is lacking, the challenges and potential pitfalls in
pursuing such studies are substantial. These challenges
include a large sample size and expense as well as a
complicated study design. Most would advocate randomiz-
ing the study population to receive the screening test or not
and then utilizing various intensities of lipid-lowering
therapy based on how the screening test might influence
perceived risk.
Should the basis for trial inclusion be the presence of
multiple ASCVD risk factors or by FRS criteria? Should
lipid-lowering therapy be mandated by the study protocol,
and if so, what lipid-lowering algorithm should be used?
Should such a study be placebo controlled as opposed to
comparing various intensities of lipid-lowering therapy?
Given that statin therapy is now generally used aggressively
by many clinicians for intermediate-risk patients even with-
out imaging tests, the power to show an incremental gain
when adding an imaging test may prove to be limited.
It is likely that most men over the age of 55 years and
women over the age of 65 years will have some degree of
coronary calcification. Are we then obligated to treat them
with at least a low-dose statin and aspirin if they have below
average CAC for their age, and use a high dose of a potent
statin only for those with Agatston scores100 or for those
with scores 75th percentile for their age?
How will costs and adverse effects of additional testing on
uality of life be measured? How does one track the cost and
motional anguish surrounding incidental findings such as
oncalcified lung nodules that must be followed up by 2 or
ore chest CT scans over the next 18 to 24 months to
ocument stability or make a diagnosis of possible malig-
ancy? Conversely, how does one measure the potential
ncreased motivation for lifestyle change and increased
ompliance with medication when patients can directly
isualize advanced atherosclerosis in their coronary arteries?
ppropriate design, interventions, and duration will prove
ritical and costly for such a trial, but necessary. Efforts by
he National Heart, Lung, and Blood Institute to address
his need are ongoing.
One note of caution is that a suboptimally designed or
xecuted RCT could be very confusing to clinicians and to
he public. Recently, the DIAD (Diagnostic Imaging in
symptomatic Diabetics) trial assessed whether screening
f diabetic patients with single-positron emission computed
omography myocardial perfusion imaging could enhancedetection of those with high ASCVD risk and whether the
detection of this risk was associated with an improvement in
clinical outcomes (7).
Although 22% of subjects in this study had an abnormal
myocardial perfusion imaging, only 6% of the defects were
moderate or large, and there was no ability to detect persons
with advanced subclinical atherosclerosis without overt isch-
emia. As a result, there was only a slightly higher rate of
coronary angiography in the group that was screened, but
there was no difference in the intensification of secondary
prevention measures in the screening group. Ultimately,
there was no difference in clinical events between the
screened and unscreened arms. One wonders if CAC testing
had been employed and identified persons with advanced
subclinical atherosclerosis for their age, it would likely have
resulted in more appropriate use of aggressive secondary
prevention measures, as recently demonstrated by Nasir et
al. (8) in a multiethnic population with elevated CAC
scores.
In addition to its ability to identify persons with advanced
subclinical atherosclerosis for their age, the absence of CAC
has been associated with a very low risk of cardiac events
over the next 5 years (9). That provides a rationale to
emphasize lifestyle changes and scale back on expensive
high-potency statins and focus on generic statin therapy if
the low-density lipoprotein cholesterol is 130 mg/dl
despite improved dietary and exercise habits. Clinicians may
also decide to refrain from ordering stress imaging tests in
the setting of atypical chest discomfort.
Some have suggested that one should restrict aggressive
pharmacotherapy to patients with at least moderate subclin-
ical atherosclerosis to lower the number-needed-to-treat for
expensive pharmacotherapy. For example, in the ASCOT
(Anglo-Scandinavian Cardiac Outcomes Trial), 93 adults
would have needed to be treated for a mean of 3.3 years to
prevent a single cardiac event (10). Could the use of
atherosclerosis imaging have targeted those patients likely to
benefit from aggressive pharmacotherapy and reduced the
number-needed-to-treat?
No randomized, controlled, interventional outcome trial
evaluating aggressive lipid and blood pressure lowering as
well as aspirin therapy guided by the FRS exists. The FRS
has become widely accepted as a reasonable approach to
CAD risk prediction and stratification in guiding primary
prevention on the basis of prospective, observational cohort
data. This is certainly not the first instance in which a
medical intervention or strategy is widely used or accepted
in the absence of RCT evidence of mortality benefit:
consider the examples of nitrates for myocardial ischemia,
furosemide for decompensated heart failure, oxygen for
hypoxemia, or parachutes for free fall (11).
Conservative guidelines often withhold support for a ther-
apeutic or diagnostic intervention in the absence of robust
RCT evidence. However, the absence of such evidence is not
equivalent to evidence against selective use of a diagnostic test.
In the case of imaging asymptomatic CAD, ample prospective
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use of CAC in improving risk prediction in appropriate groups
of patients (12,13), as currently reflected by several of the
guidelines reviewed by Ferket et al. (6).
In a recently published study of 5,878 participants in the
MESA (Multi-Ethnic Study of Atherosclerosis) with 209
CAD events over 6 years of follow-up, CAC correctly
reclassified one-half of the subjects deemed at intermediate
risk into both higher- and lower-risk categories (14). The
statistical methods in this study demonstrated that CAC
had an additive effect on risk prediction, with accurate
reclassification and improved estimation of risk, with the
caveats that this study used the FRS modified to account for
ethnicity for initial risk prediction and truncated 10-year
risk categories for the 5-year follow-up.
Hence, selective use of CAC in intermediate-risk popula-
tions may prove beneficial in avoiding over-treatment of some
persons while identifying others who previously would not
have qualified for intensive pharmacologic and lifestyle preven-
tion efforts based on FRS alone. There is generally a low risk
with and low cost for aspirin and generic statin therapy, and
there is a very low radiation risk of a single CT scan for CAC
screening (1 to 1.5 mSv). Withholding the potential benefits
of selective screening of persons at indeterminate risk, such as
those with family history of premature cardiovascular disease
and at least a 6% risk of a myocardial infarction over the next
decade in the absence of RCT evidence of improved mortality,
seems overly dogmatic.
Guidelines are intended to help clinicians navigate issues
and challenges in patient care by application of the best
available evidence. However, they are not dicta to which all
care decisions should perfunctorily adhere. In the case of
screening for asymptomatic CAD, a double standard exists
for what is the currently accepted standard—the FRS—and for
novel strategies for risk prediction, as there are no clamors for
an outcome-based RCT of FRS-guided interventions.
Given the difficulties inherent in generating robust RCT
evidence, judicious application of the available evidence
from well-executed prospective, observational cohort studies
is needed to continue to improve risk prediction and
primary prevention of CAD events. We must avoid the
“cognitive dissonance” that often impedes forward progress
and confines guidelines to the necessity of the RCT to
optimize the care of our patients in light of the available
evidence.
In summary, when there’s something wrong in the
neighborhood of cardiovascular risk prediction, who should
we collectively call (upon)? The data in the preceding textargue for thoughtful interpretation of the available evi-
dence as summarized in current guidelines rather than
narrow adherence to rules. We think that Dr. Venkman
would agree.
Reprint requests and correspondence: Dr. Roger S. Blumenthal,
The Johns Hopkins Ciccarone Center for the Prevention of Heart
Disease, Blalock 524C, Ciccarone Center, 600 North Wolfe
Street, Baltimore, Maryland 21287. E-mail: rblument@jhmi.edu.
REFERENCES
1. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable
risk factors associated with myocardial infarction in 52 countries (the
INTERHEART study): case-control study. Lancet 2004;364:937–52.
2. Gibbons RJ, Jones DW, Gardner TJ, et al. The American Heart
Association’s 2008 statement of principles for healthcare reform.
Circulation 2008;118:2209–18.
3. Schlendorf KH, Nasir K, Blumenthal RS. Limitations of the Framing-
ham risk score are now much clearer. Prev Med 2009;48:115–6.
4. DeMazumder D, Hasan RK, Blumenthal RS, et al. Should statin
therapy be allocated on the basis of global risk or on the basis of
randomized trial evidence? Am J Cardiol 2010;106:905–9.
5. Berger JS, Jordan CO, Lloyd-Jones D, Blumenthal RS. Screening for
cardiovascular risk in asymptomatic patients. J Am Coll Cardiol
2010;55:1169–77.
6. Ferket BS, Genders TSS, Colkesen EB, et al. Systematic review of
guidelines on imaging of asymptomatic coronary artery disease. J Am
Coll Cardiol 2011;57:1591–600.
7. Wackers FJ, Young LH. Lessons learned from the Detection of
Ischemia in Asymptomatic Diabetics (DIAD) study. J Nucl Cardiol
2009;16:855–9.
8. Nasir K, McClelland RL, Blumenthal RS, et al. Coronary artery
calcium in relation to initiation and continuation of cardiovascular
preventive medications: the Multi-Ethnic Study of Atherosclerosis
(MESA). Circ Cardiovasc Qual Outcomes 2010;3:228–35.
9. Blaha M, Budoff MJ, Shaw LJ, et al. Absence of coronary artery
calcification and all-cause mortality. J Am Coll Cardiol Img 2009;2:
692–700.
10. Sever PS, Dahlof B, Poulter NE, et al. Prevention of coronary and
stroke events with atorvastatin in hypertensive patients who have
average or lower-than-average cholesterol concentrations, in the
Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm
(ASCOT-LLA): a multicentre randomized controlled trial. Lancet
2003;36:1149–58.
11. Smith GC, Pell JP. Parachute use to prevent death and major trauma
related to gravitational challenge: systematic review of randomised
controlled trials. BMJ 2003;327:1459–61.
12. Lakoski SG, Greenland P, Wong ND, et al. Coronary artery calcium
scores and risk for cardiovascular events in women classified as “low
risk” based on Framingham risk score: the Multi-Ethnic Study of
Atherosclerosis (MESA). Arch Intern Med 2007;167:2437–42.
13. Scheuner MT, Setodji CM, Pankow JS, et al. General cardiovascular
risk profile identifies advanced coronary artery calcium and is improved
by family history: the Multi-Ethnic Study of Atherosclerosis. Circ
Cardiovasc Genet 2010;3:97–105.
14. Polonsky TS, McClelland RL, Jorgensen NW, et al. Coronary artery
calcium score and risk classification for coronary heart disease predic-
tion. JAMA 2010;303:1610–6.Key Words: coronary calcium y prevention y risk prediction.
